Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

Myelodysplastic Syndromes 3Leukemia, Myelomonocytic, Chronic 3Leukemia 3Anemia, Refractory, with Excess of Blasts 3Leukemia, Myeloid, Accelerated Phase 2Blast Crisis 2Neutropenia 1Leukemia, Myeloid, Acute 1Anemia, Refractory 1

Interventions

Cyclophosphamide 30fludarabine phosphate 25Cyclosporine 25Busulfan 20Mycophenolic Acid 18Peripheral Blood Stem Cell Transplantation 17Cord Blood Stem Cell Transplantation 16Antilymphocyte Serum 16Whole-Body Irradiation 15Radiotherapy 15Methotrexate 12Methylprednisolone 10Filgrastim 10Cytarabine 8Etoposide 7Tacrolimus 6Melphalan 6sargramostim 5fludarabine 4Thiotepa 4Granulocyte Colony-Stimulating Factor 4Decitabine 4Cyclosporins 4Azacitidine 4merphos 3Transplantation 3Arsenic Trioxide 3bryostatin 1 2aldesleukin 2Vorinostat 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Anemia, Refractory × lintuzumab × Classical hematology × Clear all
NCT00997243 2017-05-10

Azacitidine and Lintuzumab in Treating Patients With Previously Untreated Myelodysplastic Syndromes

Ohio State University Comprehensive Cancer Center

Phase 2 Terminated
7 enrolled 8 charts
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, Anemia, Refractory, with Excess of Blasts, Leukemia, Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡